EP0063132A1 - New galenical administration form of metoclopramide, method for its preparation and medicament comprising this new form. - Google Patents

New galenical administration form of metoclopramide, method for its preparation and medicament comprising this new form.

Info

Publication number
EP0063132A1
EP0063132A1 EP81902835A EP81902835A EP0063132A1 EP 0063132 A1 EP0063132 A1 EP 0063132A1 EP 81902835 A EP81902835 A EP 81902835A EP 81902835 A EP81902835 A EP 81902835A EP 0063132 A1 EP0063132 A1 EP 0063132A1
Authority
EP
European Patent Office
Prior art keywords
metoclopramide
microgranules
new
neutral
weight
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
EP81902835A
Other languages
German (de)
French (fr)
Other versions
EP0063132B1 (en
Inventor
Claude Laruelle
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of EP0063132A1 publication Critical patent/EP0063132A1/en
Application granted granted Critical
Publication of EP0063132B1 publication Critical patent/EP0063132B1/en
Expired legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol

Definitions

  • METOCLOPRAMIDE has been known for many years. In the form of dihydrochloride or monohydrochloride, it is widely used to treat functional gastrointestinal disturbances such as dyspepsia, peptic and biliary dyskinesia, chronic gastritis, peptic ulcers, nausea and vomiting. Pharmacologically, the action of METOCLOPRAMIDE is both central and peripheral. However, the administration of METOCLOPRAMIDE in its current form has significant drawbacks, limiting the convenience of use.
  • the present invention therefore relates to a new dosage form with delayed programmed release of METOCLOPRAMIDE and is characterized in that it is constituted by microgranules comprising a neutral core consisting of a grain of an inert excipient comprising at least two components of the type belonging to the class consisting of sucrose, starch, talc, drying silica, lactose and stearic acid, this neutral grain being provided with a first layer comprising METOCLOPRAMIDE, then with a second outer layer consisting of a microporous envelope comprising at least one natural and / or synthetic polymer belonging to the class consisting of shellac, gum arabic, gelatin, ethylcellulose, cellulose acetophthalate, cellulose triacetate, polyoxyethylene glycol, methacrylates, styrene-acrylonitrile copolymer and polyvinylpyrrolidone in successive envelopes.
  • a neutral core consisting of a grain of an inert excipient comprising at
  • the microporous envelope can be formed of shellac in a proportion by weight varying between 1 and 10%
  • the inert excipient can be a mixture comprising from 40 to 80% by weight of sucrose and from 10 to 40%. by weight of starch.
  • the first layer may comprise from 1 to 20% by weight of METOCLOPRAMIDE, from 0.01% to 0.5% by weight of stearic acid, from 5 to 15% by weight talc and 2 to 10% by weight of drying silica.
  • the neutral core may include adsorbates of METOCLOPRAMIDE.
  • the subject of the invention is also a process for obtaining the remarkable new galenical form in that neutral sieved and dried microgranules are prepared beforehand, that a solution in absolute alcohol of METOCLOPRAMIDE is projected onto these microgranules, then coating said microgranules to make the first layer in one or more coatings, then forming the microporous envelope by coating with said polymer in solution in a solvent.
  • the present invention relates to medicaments comprising the new form of administration of METOCLOPRAMIDE in the form of active microgranules mixed with neutral uncoated microgranules in order to obtain a predetermined concentration of METOCLOPRAMIDE, this set of microgranules being presented in the form capsules, tablets, suppositories, syrup, granules or powder.
  • METOCLOPRAMIDE The first layer is then made by incorporating the other excipients with the exception of shellac into these microgranules, then the spraying of METOCLOPRAMIDE hydrochloride is restarted, this coating being repeated several times with sieving and drying if necessary between each layer.
  • the microporous outer layer is produced by spraying the shellac with the granules in solution in absolute ethyl alcohol.
  • microporous outer envelope is made so as to allow a prolonged release of theoretical METOCLOPRAMIDE:
  • a disintegration device in which an amount of microgranules corresponding to approximately 50 mg of contact is brought into contact.
  • active principle with artificial liquids the device making it possible to maintain constant agitation and a constant temperature of 37 ° ⁇ 0.5 ° C.
  • Artificial liquids are solutions buffered at successive pH used according to the diagram below.
  • the new dosage form according to the invention was the subject of an in-depth pharmacokinetic study in comparison with the conventional tablet form.
  • the study was carried out in cross-over in humans.
  • Six male subjects received each of the two forms at two-week intervals, one 20 mg capsule of active ingredient containing the microgranules and two 10 mg tablets of the conventional form.
  • the plasma concentration of METOCLOPRAMIDE was determined by means of 10 samples in the interval of 72 hours.
  • the time of appearance of the serum peak increases from 1 hour to 4.5 hours.
  • the half-life duration increases from approximately 3 hours to more than 8 hours.
  • the new dosage presentation leads to a new drug useful for the treatment of gastric disorders in general.
  • FIGURE 1 Plasma concentrations of METOCLOPRAMIDE after an oral cross-over dose in 6 subjects . are healthy
  • FIGURE 2 Plasma concentrations of METOCLOPRAMIDE after an oral dose taken in cross-over in 6 healthy subjects
  • FIGURE 3 METOCLOPRAMIDE plasma concentrations

Landscapes

  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Medicament a base de metoclopramide presente sous une nouvelle forme galenique a effet retard. Le principe actif contenu dans des microgranules inclus dans une gelule est libere progressivement. Le nouveau medicament permet de diminuer le nombre de prises journalieres et de reduire la quantite de principe actif ingere.Metoclopramide-based drug in a new dosage form with a delayed effect. The active ingredient contained in microgranules included in a capsule is gradually released. The new drug makes it possible to reduce the number of daily intakes and to reduce the quantity of active ingredient ingested.

Description

NOUVELLE FORME GALENIQUE D'ADMINISTRATION DU METOCLOPRAMIDE, SON PROCEDE DE PREPARATION ET MEDICAMENT COMPRENANT CETTE NOUVELLE FORME La présente invention concerne une nouvelle préparation galénique du METOCLOPRAMIDE, et le médicament comprenant cette préparation. NOVEL GALENIC FORM OF ADMINISTRATION OF METOCLOPRAMIDE, ITS PREPARATION METHOD AND MEDICINAL PRODUCT COMPRISING THIS NEW FORM The present invention relates to a new galenical preparation of METOCLOPRAMIDE, and the medicament comprising this preparation.
Le METOCLOPRAMIDE est connu depuis de nombreuses années. Sous la forme de dichlorhydrate ou de monochlorhydrate, il est largement utilisé pour traiter les troublés fonctionnels gastro-intestinaux tels que dyspepsies, dyskinésies gastro-duodénales et biliaires, gastrites chroniques, ulcères gastro-duëdonaux, nausées et vomissements. Au plan pharmacologique, l'action du METOCLOPRAMIDE est à la fois centrale et périphérique. Toutefois, l'administration du METOCLOPRAMIDE sous sa forme actuelle présente des inconvénients notables, en limitant la commodité d'emploi.METOCLOPRAMIDE has been known for many years. In the form of dihydrochloride or monohydrochloride, it is widely used to treat functional gastrointestinal disturbances such as dyspepsia, peptic and biliary dyskinesia, chronic gastritis, peptic ulcers, nausea and vomiting. Pharmacologically, the action of METOCLOPRAMIDE is both central and peripheral. However, the administration of METOCLOPRAMIDE in its current form has significant drawbacks, limiting the convenience of use.
Par exemple, on a constaté que la présentation sous forme de comprimés provoque certaines intolérances, en particulier gastriques, ce qui empêche son utilisation par une catégorie importante de malades d'une part, et d'autre part qui limite son utilisation pour les traitements à long terme.For example, it has been found that the presentation in the form of tablets causes certain intolerances, in particular gastric, which prevents its use by a large category of patients on the one hand, and on the other hand which limits its use for treatments to long term.
De plus, on a constaté avec les formes disponiblés, après chaque administration, c'est-à-dire trois ou quatre fois par jour sinon davantage, une succession d'augmentations et de diminutions rapides des taux plasmatiques, l'organisme étant soumis alternativement à des surdosages et à des sous-dosages. Enfin, les inconvénients des formes classiques n'ont pas permis jusqu'à présent le traitement des troubles digestifs nécessitant une administration prolongée, ce qui est au contraire possible avec la nouvelle forme galénique d'administration du METOCLOPRAMIDE ainsi qu'on le démontre ci-après, cette nouvelle forme permettant la libération régulière du médicament dans l'organisme pendant des périodes suffisamment longues pour autoriser simplement la prise journalière d'une seule unité. La présente invention a donc pour objet une nouvelle forme galénique à libération programmée retardée du METOCLOPRAMIDE et est caractérisée en ce qu'elle est constituée par des microgranules comprenant une âme neutre constituée d'un grain d'un excipient inerte comprenant au moins deux composants du type appartenant à la classe constituée par le saccharose, l'amidon, le talc, la silice desséchante, le lactose et l'acide stéarique, ce grain neutre étant muni d'une première couche comprenant le METOCLOPRAMIDE, puis d'une seconde couche extérieure constituëe par une enveloppe microporeuse comprenant au moins un polymère naturel et/ou synthétique appartenant à la classe constituée par la gomme laque, la gomme arabique, la gélatine, l ' éthylcellulose, l ' acétophtalate de cellulose, le triacëtate de cellulose, le polyoxyéthylèneglycol, les methacrylates, le copolymère styrène-acrylonitrile et le polyvinylpyrrolidone en enveloppes successives.In addition, with the forms available, after each administration, that is to say three or four times a day if not more, there has been a succession of rapid increases and decreases in plasma levels, the organism being subjected alternately overdoses and underdoses. Finally, the drawbacks of conventional forms have not so far made it possible to treat digestive disorders requiring prolonged administration, which is on the contrary possible with the new galenic form of administration of METOCLOPRAMIDE, as demonstrated below. after, this new form allowing the regular release of the drug in the body for periods long enough to simply allow the daily intake of a single unit. The present invention therefore relates to a new dosage form with delayed programmed release of METOCLOPRAMIDE and is characterized in that it is constituted by microgranules comprising a neutral core consisting of a grain of an inert excipient comprising at least two components of the type belonging to the class consisting of sucrose, starch, talc, drying silica, lactose and stearic acid, this neutral grain being provided with a first layer comprising METOCLOPRAMIDE, then with a second outer layer consisting of a microporous envelope comprising at least one natural and / or synthetic polymer belonging to the class consisting of shellac, gum arabic, gelatin, ethylcellulose, cellulose acetophthalate, cellulose triacetate, polyoxyethylene glycol, methacrylates, styrene-acrylonitrile copolymer and polyvinylpyrrolidone in successive envelopes.
En particulier, l'enveloppe microporeuse peut Être formée de gomme laque selon une proportion en poids variant entre 1 et 10 %,et l'excipient inerte peut être un mélange comprenant de 40 à 80 % en poids de saccharose et de 10 à 40 % en poids d'amidon.In particular, the microporous envelope can be formed of shellac in a proportion by weight varying between 1 and 10%, and the inert excipient can be a mixture comprising from 40 to 80% by weight of sucrose and from 10 to 40%. by weight of starch.
Selon une forme de réalisation avantageuse de l'invention, la première couche peut comprendre de 1 à 20 % en poids de METOCLOPRAMIDE, de 0,01 % à 0,5 % en poids d'acide stéarique, de 5 à 15 % en poids de talc et de 2 à 10 % en poids de silice desséchante. En outre, l'âme neutre peut comprendre des adsorbats de METOCLOPRAMIDE. L'invention a également pour objet un procédé d'obtention de la nouvelle forme galénique remarquable en ce qu'on prépare au préalable des microgranules neutres tamisés et séchés, qu'on projette sur ces microgranules une solution dans l'alcool absolu de METOCLOPRAMIDE, qu'on enrobe ensuite lesdits microgranules pour réaliser la première couche en un ou plusieurs enrobages, puis qu'on forme l'enveloppe microporeuse par enrobage à l'aide dudit polymère en solution dans un solvant. De plus, la présente invention a pour objet des médicaments comprenant la nouvelle forme d'administration du METOCLOPRAMIDE sous forme de microgranules actifs mélangés à des microgranules neutres non enrobés afin d'obtenir une concentration prédéterminée en METOCLOPRAMIDE, cet ensemble de microgranules étant présenté sous formes de gélules, de comprimés, de suppositoires, de sirop, de granules ou de poudre.According to an advantageous embodiment of the invention, the first layer may comprise from 1 to 20% by weight of METOCLOPRAMIDE, from 0.01% to 0.5% by weight of stearic acid, from 5 to 15% by weight talc and 2 to 10% by weight of drying silica. In addition, the neutral core may include adsorbates of METOCLOPRAMIDE. The subject of the invention is also a process for obtaining the remarkable new galenical form in that neutral sieved and dried microgranules are prepared beforehand, that a solution in absolute alcohol of METOCLOPRAMIDE is projected onto these microgranules, then coating said microgranules to make the first layer in one or more coatings, then forming the microporous envelope by coating with said polymer in solution in a solvent. In addition, the present invention relates to medicaments comprising the new form of administration of METOCLOPRAMIDE in the form of active microgranules mixed with neutral uncoated microgranules in order to obtain a predetermined concentration of METOCLOPRAMIDE, this set of microgranules being presented in the form capsules, tablets, suppositories, syrup, granules or powder.
L'ensemble des caractéristiques et avantages de l'invention seront mieux compris par l'Homme de l'Art en se référant à la description qui va suivre de modes de réalisation particuliers pris à titre d'exemples non limitatifs de la nouvelle forme galénique, de son procédé et de ses applications thérapeutiques, en particulier en relation avec les contrôles pharmacologiques et cliniques effectués en utilisant la nouvelle forme galénique.All of the characteristics and advantages of the invention will be better understood by those skilled in the art with reference to the description which follows of particular embodiments taken by way of nonlimiting examples of the new galenical form, of its process and its therapeutic applications, in particular in relation to the pharmacological and clinical checks carried out using the new galenical form.
EXEMPLE DE PREPARATION DE LA NOUVELLE FORME GALENIQUE : On indique ci-après, l'exemple de fabrication correspondant à 100 000 gélules dosées à 20 mg de chlorhydrate de METOCLOPRAMIDE. a) Formule de fabriçation :EXAMPLE OF PREPARATION OF THE NEW GALENIC FORM: The manufacturing example corresponding to 100,000 capsules containing 20 mg of METOCLOPRAMIDE hydrochloride is indicated below. a) Manufacturing formula:
- METOCLOPRAMIDE (dichlorhydrate monohydrate) .... 2,0 kg- METOCLOPRAMIDE (dihydrochloride monohydrate) .... 2.0 kg
- saccharose- sucrose
- amidon de mais- corn starch
- acide stéarique - gomme laque- stearic acid - shellac
- polymères mêthacryliques- methacrylic polymers
- talc - polyvidone- talc - polyvidone
- édétate de sodium- sodium edetate
- alcool éthylique absolu qs 21, 0 kg b) Procédé de préparation : On granule de l'amidon de mais et du saccharose, puis on tamise et on turbine longuement les grains de façon à les rendre parfaitement sphériques ; on tamise à nouveau et on sèche parfaitement. Dans un mélangeur en acier inoxydable, on projette sur les âmes neutres ainsi obtenues, une solution alcoolique de chlorhydrate de- absolute ethyl alcohol qs 21.0 kg b) Preparation process : Granulate corn starch and sucrose, then sift and turbine the grains for a long time so as to make them perfectly spherical; we sift again and dry perfectly. In an stainless steel mixer, an alcoholic solution of hydrochloride is sprayed onto the neutral cores thus obtained.
METOCLOPRAMIDE. On réalise ensuite la première couche en incorporant à ces microgranules les autres excipients à l'exception de la gomme laque, puis on recommence la pulvérisation de chlorhydrate de METOCLOPRAMIDE, cet enrobage étant recommencé plusieurs fois avec tamisage et séchage si nécessaire entre chaque couche.METOCLOPRAMIDE. The first layer is then made by incorporating the other excipients with the exception of shellac into these microgranules, then the spraying of METOCLOPRAMIDE hydrochloride is restarted, this coating being repeated several times with sieving and drying if necessary between each layer.
Lorsque la première couche contenant le principe actif est terminée, on réalise la couche extérieure microporeuse en projetant sur les granules la gomme laque en solution dans l'alcool éthylique absolu.When the first layer containing the active ingredient is completed, the microporous outer layer is produced by spraying the shellac with the granules in solution in absolute ethyl alcohol.
On sèche ensuite soigneusement en éliminant l'alcool éthylique restant, on tamise à nouveau et on contrôle comme ci-après le titre des microgranules obtenus avant de mettre en gélules après avoir ajusté ëventuel lement le titrage par addition et homogénéisé avec des microgranules neutres pour arriver au titrage désiré de 20 mg de METOCLOPRAMIDE. MESURE DE LA LIBERATION DU METOCLOPRAMIDEIt is then carefully dried, eliminating the remaining ethyl alcohol, it is again sieved and the title of the microgranules obtained is checked as below, before putting into capsules after having possibly adjusted the titration by addition and homogenized with neutral microgranules to arrive at the desired titration of 20 mg of METOCLOPRAMIDE. MEASUREMENT OF METOCLOPRAMIDE RELEASE
L'enveloppe extérieure microporeuse est réalisée de manière à permettre une libération prolongée de METOCLOPRAMIDE théorique :The microporous outer envelope is made so as to allow a prolonged release of theoretical METOCLOPRAMIDE:
1ère heure : libération inférieure à 40 % ; 4ème heure : libération inférieure à 75 % ; 8ème heure : libération supérieure à 80 %. Pour contrôler cette caractéristique, on utilise un appareil à délitement dans lequel on met en contact une quantité de microgranules correspondant à environ 50 mg de principe actif avec des liquides artificiels, l'appareil permettant de maintenir une agitation constante et une température constante de 37° ± 0,5°C. Les liquides artificiels sont des solutions tamponnées à pH successifs utilisés selon le schéma ci-dessous.1st hour: release less than 40%; 4th hour: release less than 75%; 8th hour: release greater than 80%. To control this characteristic, a disintegration device is used in which an amount of microgranules corresponding to approximately 50 mg of contact is brought into contact. active principle with artificial liquids, the device making it possible to maintain constant agitation and a constant temperature of 37 ° ± 0.5 ° C. Artificial liquids are solutions buffered at successive pH used according to the diagram below.
RESULTATS SOLUTIONS TEMPS DE LIBERATION pH THEORIQUES REELSRESULTS SOLUTIONS RELEASE TIMES REAL THEORETICAL pH
25 ml liquide gastrique 1 heure (1ère heure) 1,5 < 40 % 36 % 25 ml liquide intestinal 1 heure (2ème heure) 4,5 > 40 %25 ml gastric fluid 1 hour (1st hour) 1.5 <40% 36% 25 ml intestinal fluid 1 hour (2nd hour) 4.5> 40%
25 ml liquide 2 heures (3ème et intestinal 4ème heures) 6,9 < 75 % 70,8 %25 ml liquid 2 hours (3rd and intestinal 4th hours) 6.9 <75% 70.8%
25 ml liquide 2 heures (5ême et intestinal 6ème heures) 6,9 > 75 % 25 ml liquide 2 heures (7ème et intestinal - 8ème heures) 7,2 > 80 % 92,3 %25 ml liquid 2 hours (5th and intestinal 6th hours) 6.9> 75% 25 ml liquid 2 hours (7th and intestinal - 8th hours) 7.2> 80% 92.3%
La nouvelle forme galénique selon l'invention a fait l'objet d'une étude pharmacocine tique approfondie en comparaison avec la forme comprimé classique. L'étude a été effectuée en cross-over chez l'homme. Six sujets de sexe masculin recevaient chacune des deux formes à deux semaines d'intervalle, une gélule de 20 mg de principe actif contenant les microgranules et 2 comprimés à 10 mg de la forme classique. La détermination de la concentration plasmatique du METOCLOPRAMIDE a été effectuée au moyen de 10 prélèvements dans l'intervalle de 72 heures.The new dosage form according to the invention was the subject of an in-depth pharmacokinetic study in comparison with the conventional tablet form. The study was carried out in cross-over in humans. Six male subjects received each of the two forms at two-week intervals, one 20 mg capsule of active ingredient containing the microgranules and two 10 mg tablets of the conventional form. The plasma concentration of METOCLOPRAMIDE was determined by means of 10 samples in the interval of 72 hours.
Au terme de l'étude, les conclusions sont les suivantes : - la biodisponibilitë relative n'est pas modifiée de manière significative.At the end of the study, the conclusions are as follows: - the relative bioavailability is not significantly modified.
- Le temps d'apparition du pic sérique passe de 1 heure à 4 heures et demie.- The time of appearance of the serum peak increases from 1 hour to 4.5 hours.
- La durée de demi-vie passe de 3 heures environ à plus de 8 heures.- The half-life duration increases from approximately 3 hours to more than 8 hours.
- Les deux formulations sont bio-inéquivalentes.- The two formulations are bio-unequal.
- L'étude des courbes obtenues montre qu'une gélule à 20 mg équivaut à 2 comprimés au minimum, sinon 3 comprimés à 10 mg .- The study of the curves obtained shows that a capsule with 20 mg is equivalent to a minimum of 2 tablets, otherwise 3 10 mg tablets.
Afin d ' illustrer les caractéristiques de l ' invention rapportée ci-dessus , 3 graphiques sont présentés. En outre , l ' étude toxicologique eff ectuée sur le rat a permis de déterminer la dose léthale 50 % lorsque les microgranules sont administrés par voie orale :In order to illustrate the characteristics of the invention reported above, 3 graphics are presented. In addition, the toxicological study carried out on the rat made it possible to determine the lethal dose 50% when the microgranules are administered orally:
- chez les femelles, la mortalité est de 50 % à 9,2 g/kg;- in females, the mortality is 50% at 9.2 g / kg;
- chez les mâles, la mortalité est de 40 % à 20 g/kg. Au plan clinique, la tolérance de la nouvelle présentation a été bonne dans l'ensemble et supérieure à la présentation classique. Elle permet ainsi de pratiquer des traitements de longue durée sans inconvénient notable pour le patient. De plus, du fait de l'économie de 35 % à 50 % en dosage de principe actif, on obtient donc une utilisation thérapeutique améliorée justifiant l'intérêt de la nouvelle présentation galénique.- in males, mortality is 40% at 20 g / kg. Clinically, the tolerance of the new presentation was generally good and superior to the classic presentation. It thus makes it possible to practice long-term treatments without significant disadvantage for the patient. In addition, due to the savings of 35% to 50% in dosage of active principle, an improved therapeutic use is therefore obtained, justifying the advantage of the new galenic presentation.
Par conséquent, on peut affirmer que la nouvelle présentation galénique conduit à un nouveau médicament utile pour le traitement des troubles gastriques en général.Therefore, it can be said that the new dosage presentation leads to a new drug useful for the treatment of gastric disorders in general.
Elle permet d'assurer une libération du METOCLOPRAMIDE de façon contrôlée et indépendamment de la façon dont les microgranules sont administrés avec une courbe de libération du principe actif constante d'un malade à l'autre et d'une prise à l'autre.It makes it possible to ensure release of METOCLOPRAMIDE in a controlled manner and independently of the way in which the microgranules are administered with a release curve of the active principle which is constant from one patient to another and from one intake to another.
Enfin, elle permet une mise en gélules et assure la stabilité du METOCLOPRAMIDE, ce qui est une amélioration industrielle et médicale importante.Finally, it allows capsules and ensures the stability of METOCLOPRAMIDE, which is an important industrial and medical improvement.
Bien entendu, l'Homme de l'Art pourra trouver d'autres avantages et variantes de l'invention, en particulier en ce qui concerne le procédé d'obtention des microgranules ou les modifications de dosage, sans pour cela sortir du cadre et de la portée de la présente invention. EXPLICATIONS DES FIGURES FIGURE 1 : Concentrations plasmatiques de METOCLOPRAMIDE après une prise orale effectuée en cross-over chez 6 suj.ets sainsOf course, those skilled in the art will be able to find other advantages and variants of the invention, in particular with regard to the process for obtaining microgranules or the modifications of dosage, without thereby departing from the scope and the scope of the present invention. EXPLANATION OF FIGURES FIGURE 1: Plasma concentrations of METOCLOPRAMIDE after an oral cross-over dose in 6 subjects . are healthy
- 2 comprimés à 10 mg ( )- 2 tablets of 10 mg ()
- 1 gélule retard à 20 mg ( )- 1 20 mg retard capsule ()
FIGURE 2 : Concentrations plasmatiques de METOCLOPRAMIDE après une prise orale effectuée en cross-over chez 6 sujets sainsFIGURE 2: Plasma concentrations of METOCLOPRAMIDE after an oral dose taken in cross-over in 6 healthy subjects
- gélule retard à 20 mg ( )- 20 mg delay capsule ()
- comprimé à 10 mg ( )- 10 mg tablet ()
FIGURE 3 : Concentrations plasmatiques de METOCLOPRAMIDEFIGURE 3: METOCLOPRAMIDE plasma concentrations
- après trois prises orales à 7 H, 13 H, 19 H d'un comprimé à 10 mg ( )- after three oral doses at 7 a.m., 1 p.m., 7 p.m. of a 10 mg tablet ()
- après une prise orale à 7 H d'une gélule retard à 20 mg ( ) - after a 7 mg oral capsule taken at 20 mg ()

Claims

REVENDICATIONS 1°- Nouvelle forme galénique du METOCLOPRAMIDE, caractérisée en ce qu'elle est constituée par des microgranules comprenant une âme neutre constituée d'un grain d'un excipient inerte comprenant au moins deux composants du type appartenant à la classe constituée par le saccharose, l'amidon, le talc, la silice desséchante, le lactose et l'acide stéarique, ce grain neutre étant muni d'une première couche comprenant le METOCLOPRAMIDE , puis d'une seconde couche extérieure constituée par une enveloppe microporeuse comprenant au moins un polymère naturel et/ou synthétique appartenant à la classe constituée par la gomme laque, la gomme arabique, la gélatine, l'ëthylcellulose, l'acétophtaïate de cellulose, le triacétate de cellulose, le polyoxyéthylèneglycol, les methacrylates, le copolymère styrène-acrylonitrile et la polyvinylpyrrolidone.1 ° - New dosage form of METOCLOPRAMIDE, characterized in that it consists of microgranules comprising a neutral core consisting of a grain of an inert excipient comprising at least two components of the type belonging to the class constituted by sucrose , starch, talc, drying silica, lactose and stearic acid, this neutral grain being provided with a first layer comprising METOCLOPRAMIDE, then with a second outer layer constituted by a microporous envelope comprising at least one natural and / or synthetic polymer belonging to the class consisting of shellac, gum arabic, gelatin, ethylcellulose, cellulose acetophtaiate, cellulose triacetate, polyoxyethylene glycol, methacrylates, styrene-acrylonitrile copolymer and polyvinylpyrrolidone.
2°- Nouvelle forme galénique du METOCLOPRAMIDE selon la Revendication 1, caractérisée en ce que l'enveloppe microporeuse est formée de gomme laque selon une proportion en poids comprise entre 1 et 10 %.2 ° - New dosage form of METOCLOPRAMIDE according to Claim 1, characterized in that the microporous envelope is formed of shellac in a proportion by weight of between 1 and 10%.
3°- Nouvelle forme galénique du METOCLOPRAMIDE selon les Revendications 1 ou 2 , caractérisée en ce que l'excipient inerte de l'âme neutre est un mélange comprenant de 40 à 80 % en poids de saccharose et de 10 à 40 % en poids d'amidon.3 ° - New dosage form of METOCLOPRAMIDE according to Claims 1 or 2, characterized in that the inert excipient of the neutral core is a mixture comprising from 40 to 80% by weight of sucrose and from 10 to 40% by weight of 'starch.
4°- Nouvelle forme selon l'une quelconque des Revendications 1 à 3, caractérisée en ce que la première couche comprend de 1 à 20 % en poids de METOCLOPRAMIDE, de 0,01 à 0,5 % en poids d'acide stéarique, de 5 à 15 % en poids de talc.4 ° - New form according to any one of Claims 1 to 3, characterized in that the first layer comprises from 1 to 20% by weight of METOCLOPRAMIDE, from 0.01 to 0.5% by weight of stearic acid, from 5 to 15% by weight of talc.
5°- Nouvelle forme selon l'une quelconque des Revendications 1 à 4, caractérisée en ce que l'âme neutre comprend des adsorbats de METOCLOPRAMIDE. 6°- Procédé d'obtention de la nouvelle forme galénique selon l'une quelconque des Revendications 1 à 5, caractérisé en ce qu'on prépare des microgranules neutres tamisés et séchés, qu'on projette sur ces microgranules neutres une solution dans l'alcool absolu de METOCLOPRAMIDE sous forme de microgranules conformes à l'une des Revendications 1 à 5, et en ce que lesdits microgranules sont mélangés avec des microgranules neutres non enrobés afin d'obtenir une concentration prédéterminée en METOCLOPRAMIDE.5 ° - New form according to any one of Claims 1 to 4, characterized in that the neutral core comprises adsorbates of METOCLOPRAMIDE. 6 ° - Process for obtaining the new dosage form according to any one of Claims 1 to 5, characterized in that neutral microgranules are prepared sieved and dried, sprayed on these neutral microgranules with an absolute alcohol solution of METOCLOPRAMIDE in the form of microgranules in accordance with one of Claims 1 to 5, and in that said microgranules are mixed with uncoated neutral microgranules in order to obtain a predetermined concentration of METOCLOPRAMIDE.
7°- Médicaments caractérisés en ce qu'ils comprennent la nouvelle forme galénique d'administration du METOCLOPRAMIDE sous forme de microgranules conformes à l'une quelconque des Revendications 1 à 5, et en ce que lesdits microgranules sont mélangés avec des microgranules neutres non enrobés afin d'obtenir une concentration prédéterminée en METOCLOPRAMIDE.7 ° - Medicaments characterized in that they comprise the new galenical form of administration of METOCLOPRAMIDE in the form of microgranules in accordance with any one of Claims 1 to 5, and in that said microgranules are mixed with uncoated neutral microgranules in order to obtain a predetermined concentration of METOCLOPRAMIDE.
8°- Médicaments utilisés en médecine humaine, destinés au traitement des troubles gastriques, selon la Revendication 7, caractérisés en ce qu'ils se présentent sous forme de gélules, de comprimés, de suppositoires, de sirop, de granules ou de poudre. 8 ° - Medicines used in human medicine, intended for the treatment of gastric disorders, according to Claim 7, characterized in that they are in the form of capsules, tablets, suppositories, syrup, granules or powder.
EP81902835A 1980-10-28 1981-10-22 New galenical administration form of metoclopramide, method for its preparation and medicament comprising this new form Expired EP0063132B1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR8023028A FR2492661A1 (en) 1980-10-28 1980-10-28 NOVEL GALENIC FORM OF ADMINISTRATION OF METOCLOPRAMIDE, ITS PREPARATION METHOD AND MEDICINAL PRODUCT COMPRISING THIS NOVEL FORM
FR8023028 1980-10-28

Publications (2)

Publication Number Publication Date
EP0063132A1 true EP0063132A1 (en) 1982-10-27
EP0063132B1 EP0063132B1 (en) 1986-07-30

Family

ID=9247410

Family Applications (1)

Application Number Title Priority Date Filing Date
EP81902835A Expired EP0063132B1 (en) 1980-10-28 1981-10-22 New galenical administration form of metoclopramide, method for its preparation and medicament comprising this new form

Country Status (13)

Country Link
US (1) US4656024A (en)
EP (1) EP0063132B1 (en)
JP (1) JPH0428685B2 (en)
AU (1) AU555512B2 (en)
BE (1) BE890808A (en)
CA (1) CA1166574A (en)
CH (1) CH650922A5 (en)
ES (1) ES8301633A1 (en)
FR (1) FR2492661A1 (en)
GR (1) GR74683B (en)
IT (1) IT1139645B (en)
WO (1) WO1982001468A1 (en)
ZA (1) ZA816993B (en)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2534139B1 (en) * 1982-10-07 1986-08-29 Laruelle Claude NOVEL GALENIC FORM OF SULPIRIDE, METHOD FOR PREPARING SAME, AND MEDICINAL PRODUCT COMPRISING THIS NEW FORM
FR2539995B1 (en) * 1983-01-28 1985-08-16 Sanofi Sa PROGRAMMED RELEASE MEDICINE BASED ON ACETYLSALICYLIC ACID
FR2556964A1 (en) * 1983-12-23 1985-06-28 Ile De France NEW GALENIC FORMS OF SULPIRIDE USED ORALALLY
DE3403329A1 (en) * 1984-02-01 1985-08-01 Horst Dr. 4019 Monheim Zerbe PHARMACEUTICAL PRODUCT IN THE FORM OF PELLETS WITH CONTINUOUS, DELAYED DELIVERY OF ACTIVE SUBSTANCES
GB8412585D0 (en) * 1984-05-17 1984-06-20 Beecham Group Plc Composition
IT1176853B (en) * 1984-10-02 1987-08-18 Eurand Spa PROCEDURE FOR OBTAINING A CONTROLLED RELEASE FORMULATION OF WATER SOLUBLE COMPONENTS
JPS6261916A (en) * 1985-09-12 1987-03-18 Fujisawa Pharmaceut Co Ltd Long-acting drug
LU86077A1 (en) * 1985-09-18 1987-04-02 Pharlyse Sa NEW GALENIC FORMS OF VERAPAMIL, THEIR MANUFACTURE AND THE MEDICINAL PRODUCTS CONTAINING THESE NEW GALENIC FORMS
DE3712095A1 (en) * 1987-04-10 1988-10-20 Lentia Gmbh BINDER-FREE GRANULES WITH DELAYED DELIVERY OF ACTIVE SUBSTANCES
DE4131276B4 (en) * 1990-09-28 2007-07-19 Solvay Pharmaceuticals Gmbh Perorally administrable metoclopramide solutions
US5286495A (en) * 1992-05-11 1994-02-15 University Of Florida Process for microencapsulating cells
EP1202745A4 (en) * 1999-08-16 2004-09-22 Henceforth Hibernia Inc Therapeutic and prophylactic compositions including catalytic biomimetic solids and methods to prepare and use them
ATE376826T1 (en) * 2001-09-28 2007-11-15 Mcneil Ppc Inc MODIFIED RELEASE PHARMACEUTICAL FORMS
MX2008004268A (en) * 2008-03-28 2009-09-28 Posi Visionary Solutions Llp 24-hour sustained-release metoclopramide.
MX2008004267A (en) * 2008-03-28 2009-09-28 Posi Visionary Solutions Llp 24-hour sustained-release metoclopramide.

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2963402A (en) * 1955-01-18 1960-12-06 Nysco Lab Inc Sustained release medicament
FR1347413A (en) * 1963-01-29 1963-12-27 Italnysco S P A Broad-acting spherules or globules and method for their preparation
BE787973A (en) * 1971-09-04 1973-02-26 Beecham Group Ltd DELAY-EFFECT PHARMACEUTICAL TABLETS
FR2313915A1 (en) * 1976-01-26 1977-01-07 Corneille Gilbert Sustained release vincamine microcapsules - with inert core, vincamine (deriv.) intermediate layer and microporous outer coating
LU77353A1 (en) * 1977-05-16 1979-01-19
FR2397840B1 (en) * 1977-07-22 1981-03-20 Cherqui Jean
FR2432313A1 (en) * 1978-08-01 1980-02-29 Foulhoux Pierre Micro:granules contg. beta-histine - for controlled release and less side effects useful in treating Menieres syndrome
BE876857A (en) * 1979-06-08 1979-10-01 Trenker Ady METOCLOPRAMIDE RESINATE.

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO8201468A1 *

Also Published As

Publication number Publication date
JPS57502121A (en) 1982-12-02
WO1982001468A1 (en) 1982-05-13
IT1139645B (en) 1986-09-24
FR2492661B1 (en) 1983-07-18
ES506654A0 (en) 1983-01-01
CH650922A5 (en) 1985-08-30
JPH0428685B2 (en) 1992-05-15
EP0063132B1 (en) 1986-07-30
BE890808A (en) 1982-04-21
GR74683B (en) 1984-07-03
ES8301633A1 (en) 1983-01-01
AU555512B2 (en) 1986-09-25
FR2492661A1 (en) 1982-04-30
CA1166574A (en) 1984-05-01
AU7720481A (en) 1982-05-21
IT8124601A0 (en) 1981-10-21
ZA816993B (en) 1982-09-29
US4656024A (en) 1987-04-07

Similar Documents

Publication Publication Date Title
FR2494112A1 (en)
US5296232A (en) Pharmaceutical formulation which does not induce tolerance
EP0063132B1 (en) New galenical administration form of metoclopramide, method for its preparation and medicament comprising this new form
EP0385846B1 (en) Sustained-release pharmaceutical composition containing valproic acid
US4415547A (en) Sustained-release pharmaceutical tablet and process for preparation thereof
UA52679C2 (en) Pharmaceutical multiple unit formulation and method for its preparation
CA2685591A1 (en) Pharmaceutical nimodipine compositions
BE1015217A5 (en)
JPH072635B2 (en) Novel pharmaceutical preparation and method for producing the same
WO1995005166A1 (en) Procedure for encapsulating nsaids
IE53543B1 (en) New oral dipyridamole preparations
NO171827B (en) METHOD OF PREPARING A PREPARATION FOR RETARDED SEPARATION OF THEOPHYLLINE
AU2015389109B2 (en) Enteric-coated pellets containing a proton pump inhibitor
BE897863A (en) NOVEL GALENIC FORM OF SULPIRIDE, METHOD FOR PREPARING SAME, AND MEDICINAL PRODUCT COMPRISING THIS NEW FORM.
JPH03118335A (en) Flavor-masked and micro-capsulated non-steroid anti-inflammatory water- insoluble drug
JP2022549833A (en) Oral immediate release pharmaceutical composition and method of weight loss treatment
KR101067224B1 (en) Controlled releasing syrup containing ibuprofen and its manufacturing method
EP0483320B1 (en) Slow release pharmaceutical compositions to be orally administered, and method for preparing same
WO1985002114A1 (en) New galenic forms of sulpiride which may be orally administered
JP2000510104A (en) Taste sensation paracetamol composition
EP0412877A1 (en) Oral galenic form to improve bioavailability
WO2001097635A2 (en) Microcapsules containing arginine and the different uses thereof
RU2309731C1 (en) Emetine hydrochloride granulate, method for its preparing and medicinal formulation based on thereof
CN107582553A (en) A kind of drug compound preparation for treating acute gastritis
EP0115976A1 (en) Drug with programmed release containing acetylsalicylic acid

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

AK Designated contracting states

Designated state(s): AT DE GB LU NL SE

17P Request for examination filed

Effective date: 19821104

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): DE GB LU NL SE

REF Corresponds to:

Ref document number: 3175039

Country of ref document: DE

Date of ref document: 19860904

PLBI Opposition filed

Free format text: ORIGINAL CODE: 0009260

26 Opposition filed

Opponent name: DURACHEMIE GMBH & CO. KG

Effective date: 19870430

Opponent name: HEXAL-CHEMIE GMBH & CO. KG

Effective date: 19870430

NLR1 Nl: opposition has been filed with the epo

Opponent name: DURACHEMIE GMBH & CO KG

Opponent name: HEXAL CHEMIE GMBH & CO KG

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: GB

Payment date: 19910913

Year of fee payment: 11

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: LU

Payment date: 19910926

Year of fee payment: 11

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: SE

Payment date: 19911022

Year of fee payment: 11

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: NL

Payment date: 19911031

Year of fee payment: 11

EPTA Lu: last paid annual fee
PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 19921022

Ref country code: GB

Effective date: 19921022

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SE

Effective date: 19921023

PLBM Termination of opposition procedure: date of legal effect published

Free format text: ORIGINAL CODE: 0009276

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: OPPOSITION PROCEDURE CLOSED

27C Opposition proceedings terminated

Effective date: 19920907

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: NL

Effective date: 19930501

GBPC Gb: european patent ceased through non-payment of renewal fee

Effective date: 19921022

NLV4 Nl: lapsed or anulled due to non-payment of the annual fee
PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: DE

Payment date: 19941020

Year of fee payment: 14

EUG Se: european patent has lapsed

Ref document number: 81902835.8

Effective date: 19930510

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: DE

Effective date: 19960702